MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

DNMT1 level and global DNA methylation in CD45+ blood cells in Parkinson’s disease

A. Lavrinova, A. Zhuravlev, I. Miliukhina, E. Belykh, A. Tyurin, O. Berkovich, S. Pchelina, A. Emelyanov (Gatchina, Russian Federation)

Meeting: 2022 International Congress

Abstract Number: 1341

Keywords: Alpha-synuclein, Parkinson’s

Category: Parkinson's Disease: Molecular Mechanisms of Disease

Objective: The aim of our study was to assess the alterations in DNA methyltransferase1 (DNMT1) level and global DNA methylation (5-mC) in CD45+ blood cells from PD patients and controls.

Background: Alpha-synuclein (SNCA) oligomers are believed to be the major neurotoxic agents in neurodegenerative process in Parkinson’s disease (PD). SNCA gene expression has been shown to be regulated by DNA SNCA-intron1 methylation status. DNMT1 is a DNA methylation enzyme predominantly involved in the maintenance of DNA methylation during cell division.

Method: This study included 43 PD patients (mean age 66.24±7.05 years) and 47 healthy individuals (mean age of 60.09±7.21 years) as the control group. All subjects were residents from the North-Western region of Russia and provided informed consent. The study was approved by the local ethics committee. CD45+ cells were isolated from peripheral blood by density gradient centrifugation followed by magnetic separation of a homogeneous fraction of CD45+ cells using CD45+ MicroBeads and MACS Columns. The level of DNMT1 and global DNA methylation were estimated by ELISA and ELISA-like colorimetric methods, respectively. Statistical analysis was performed using SPSS 21.0.

Results: The level of DNMT1 in CD45+ blood cells was decreased in PD patients compared to control (p<0.001). No differences between PD patients and controls in global DNA methylation were found (p=0.34).

Conclusion: Our data suggest the involvement of DNMT1in PD pathogenesis.

References: This research has been supported by the Ministry of Education and Science of the Russian Federation (grant number №121060200125-2).

To cite this abstract in AMA style:

A. Lavrinova, A. Zhuravlev, I. Miliukhina, E. Belykh, A. Tyurin, O. Berkovich, S. Pchelina, A. Emelyanov. DNMT1 level and global DNA methylation in CD45+ blood cells in Parkinson’s disease [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/dnmt1-level-and-global-dna-methylation-in-cd45-blood-cells-in-parkinsons-disease/. Accessed September 28, 2023.
  • Tweet
  • Email
  • Print

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/dnmt1-level-and-global-dna-methylation-in-cd45-blood-cells-in-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Welcome to the MDS Abstracts Site
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Advanced Search
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Welcome to the MDS Abstracts Site
  • Advanced Search
  • #23972 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Patients with Essential Tremor Live Longer than their Relatives
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Insulin dependent diabetes and hand tremor
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley